Search Antibody Database

Found 1 matching record:

Displaying record number 454

Download this epitope record as JSON.

MAb ID	CGP 47 439 (CGP 47,439)
HXB2 Location	gp160(304-322) DNA(7134..7190)	gp160 Epitope Map
Author Location	gp120
Epitope	`RKRIRIQRGPGRAFVTIGK?`	Epitope Alignment
Ab Type	gp120 V3 // V3 glycan (V3g)
Neutralizing	L
Species (Isotype)	human, mouse
Patient
Immunogen	vaccine
Keywords	antibody generation, immunotherapy, neutralization, review

Vaccine Details

Vaccine type	protein
Vaccine strain	B clade IIIB
Vaccine component	gp120

Notes

Showing 6 of 6 notes.

CGP 47 439: CGP 47 439 is a BAT123 chimera that has a human IgG1 Fc domain. Liou1989 (antibody generation)
CGP 47,439: A review about the in vivo efficacy of CGP 47,439 and other MAbs against HIV-1, and about inhibition of HIV-1 infection by Ab fragments Fab, scFv and engineered human Ab variable domains or "domain antibodies" (dAbs). Chen2009b (neutralization, immunotherapy, review)
CGP 47 439: Review of passive immunotherapy, summarizing Gunthard1994 in relation to other studies Jacobson1998. Gunthard1994,Jacobson1998
CGP 47 439: Post-exposure passive transfer of murine BAT123 can confer protection to hu-PBL-SCID mice challenged with HIV-1 LAI -- this protection is not elicited by CGP 47 439, suggesting that the protection is mediated by complement -- the protective ability of BAT123 is lost when mice were treated with cobra venom factor, which inactivates serum complement -- in this circumstance complement activation provided a protective advantage. Gauduin1998
CGP 47 439: Phase I/IIA clinical trial studying multidose tolerability, immunogenicity and pharmacokinetic responses -- GP 47 439 was well tolerated, serum t_1/2 was 8-16 days, and a virus burden reduction was noted in some patients. Gunthard1994
CGP 47 439: passive transfer to Hu-PBS-SCID mice confers protection against challenge with homologous cell-free virus -- CGP 47 439 is a BAT123-human Ig chimera. Safrit1993

References

Showing 6 of 6 references.

Isolation Paper
Liou1989 R. S. Liou, E. M. Rosen, M. S. C. Fung, W. N. C. Sun, C. Sun, W. Gordon, N. T. Chang, and T. W. Chang. A Chimeric Mouse-Human Antibody That Retains Specificity for HIV-1 gp120 and Mediates the Lysis of the HIV-1-Infected Cells. J. Immunol., 143:3967-3975, 1989. PubMed ID: 2480382. Show all entries for this paper.

Chen2009b Weizao Chen and Dimiter S. Dimitrov. Human Monoclonal Antibodies and Engineered Antibody Domains as HIV-1 Entry Inhibitors. Curr. Opin. HIV AIDS, 4(2):112-117, Mar 2009. PubMed ID: 19339949. Show all entries for this paper.

Gauduin1998 M. C. Gauduin, R. Weir, M. S. Fung, and R. A. Koup. Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses, 14:205-11, 1998. Post-exposure passive transfer of murine BAT123 can confer protection to hu-PBL-SCID mice challenged with HIV-1 LAI, and the mechanism is by complement-mediated cytolysis or virolysis. This protection was not conferred by CGP 47 439, a BAT123 chimera that has a human IgG$_1$ Fc domain, substituted in place of a murine IgG$_1$ Fc domain, suggesting that the protection is mediated by complement. Further evidence was that the protective ability of BAT123 is lost when mice were treated with cobra venom factor, which inactivates serum complement. IgG$_1$ does not fix complement efficiently, so an IgG$_2$ MAb might perform better. Therefore, in spite of the potential for enhancement in some circumstances, in this circumstance complement activation provided a protective advantage. PubMed ID: 9491910. Show all entries for this paper.

Gunthard1994 H. F. Gunthard, P. L. Gowland, J. Schupbach, M. S. C. Fung, J. Boni, R.-S. Liou, N. T. Chang, P. Grob, P. Graepel, D. G. Braun, and R. Luthy. A Phase I/IIA Clinical Study with a Chimeric Mouse-Human Monoclonal Antibody to the V3 Loop of Human Immunodeficiency Virus Type I gp120. J. Infect. Dis., 170:1384-1393, 1994. PubMed ID: 7995976. Show all entries for this paper.

Jacobson1998 J. M. Jacobson. Passive Immunization for the Treatment of HIV Infection. Mt. Sinai J. Med., 65:22-26, 1998. Review. PubMed ID: 9458680. Show all entries for this paper.

Safrit1993 J. T. Safrit, M. S. C. Fung, C. A. Andrews, D. G. Braun, W. N. C. Sun, T. W. Chang, and R. A. Koup. hu-PBL-SCID Mice Can Be Protected from HIV-1 Infection by Passive Transfer of Monoclonal Antibody to the Principal Neutralizing Determinant of Envelope gp120. AIDS, 7:15-21, 1993. PubMed ID: 7680205. Show all entries for this paper.